Skip to main content

Primary Disease

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
liposomal cytarabinePhase 21 trial
Active Trials
NCT01325194Completed143Est. Dec 2019
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
liposomal cytarabinePhase 2
Stallergenes Greer
Stallergenes GreerFrance - Antony
1 program
300 IRPHASE_31 trial
Active Trials
NCT00803244Completed381Est. Jan 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Stallergenes Greer300 IR
Nordic Pharmaliposomal cytarabine

Clinical Trials (2)

Total enrollment: 524 patients across 2 trials

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Start: Jan 2009Est. completion: Jan 2010381 patients
Phase 3Completed
NCT01325194Nordic Pharmaliposomal cytarabine

CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

Start: Mar 2011Est. completion: Dec 2019143 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Primary Disease | Pipeline & Competitive Landscape | Formulate